Publication | Open Access

Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy

MedicineImmunologyColorectal CancerPathologyMetastatic Colorectal CancerImmune Checkpoint InhibitorResponse RateCancer TreatmentPharmacogenetic ProfilingOncologyRadiation Oncology